These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36755811)

  • 1. Downregulation of CAMK2N1 due to DNA Hypermethylation Mediated by DNMT1 that Promotes the Progression of Prostate Cancer.
    Peng W; Feng H; Pang L; Zhang J; Hao Y; Wei X; Xia Q; Wei Z; Song W; Wang S; Liu J; Chen K; Wang T
    J Oncol; 2023; 2023():4539045. PubMed ID: 36755811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MTSS1 hypermethylation is associated with prostate cancer progression.
    Chen J; Huang L; Zhu Q; Wang Z; Tang Z
    J Cell Physiol; 2020 Mar; 235(3):2687-2697. PubMed ID: 31541465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-129-5p promotes docetaxel resistance in prostate cancer by down-regulating CAMK2N1 expression.
    Wu C; Miao C; Tang Q; Zhou X; Xi P; Chang P; Hua L; Ni H
    J Cell Mol Med; 2020 Feb; 24(3):2098-2108. PubMed ID: 31876385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of SPDEF expression by DNA methylation in advanced prostate cancer.
    Vatanmakanian M; Steffan JJ; Koul S; Ochoa AC; Chaturvedi LS; Koul HK
    Front Endocrinol (Lausanne); 2023; 14():1156120. PubMed ID: 37900138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNMT1 Regulates Epithelial-Mesenchymal Transition and Cancer Stem Cells, Which Promotes Prostate Cancer Metastasis.
    Lee E; Wang J; Yumoto K; Jung Y; Cackowski FC; Decker AM; Li Y; Franceschi RT; Pienta KJ; Taichman RS
    Neoplasia; 2016 Sep; 18(9):553-66. PubMed ID: 27659015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of
    Yang X; Wang S; Reheman A
    Cancer Manag Res; 2020; 12():6411-6420. PubMed ID: 32801881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demethylation of the miR-146a promoter by 5-Aza-2'-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer.
    Wang X; Gao H; Ren L; Gu J; Zhang Y; Zhang Y
    BMC Cancer; 2014 May; 14():308. PubMed ID: 24885368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of EMT-Related Genes CAMK2N1 and WNT5A is increased in Locally Invasive and Metastatic Prostate Cancer.
    Carneiro I; Quintela-Vieira F; Lobo J; Moreira-Barbosa C; Menezes FD; Martins AT; Oliveira J; Silva R; Jerónimo C; Henrique R
    J Cancer; 2019; 10(24):5915-5925. PubMed ID: 31762801
    [No Abstract]   [Full Text] [Related]  

  • 9. Activation of silenced tumor suppressor genes in prostate cancer cells by a novel energy restriction-mimetic agent.
    Lin HY; Kuo YC; Weng YI; Lai IL; Huang TH; Lin SP; Niu DM; Chen CS
    Prostate; 2012 Dec; 72(16):1767-78. PubMed ID: 22539223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The circSPON2/miR-331-3p axis regulates PRMT5, an epigenetic regulator of CAMK2N1 transcription and prostate cancer progression.
    Yao B; Zhu S; Wei X; Chen MK; Feng Y; Li Z; Xu X; Zhang Y; Wang Y; Zhou J; Tang N; Ji C; Jiang P; Zhao SC; Qin C; Feng N
    Mol Cancer; 2022 May; 21(1):119. PubMed ID: 35624451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypermethylation of the CTRP9 promoter region promotes Hcy induced VSMC lipid deposition and foam cell formation via negatively regulating ER stress.
    Wang X; Ma X; Zeng Y; Xu L; Zhang M
    Sci Rep; 2023 Nov; 13(1):19438. PubMed ID: 37945738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. METTL3-mediated m
    Li WH; Dang Y; Zhang L; Zhou JC; Zhai HY; Yang Z; Ma K; Wang ZZ
    Heliyon; 2024 Apr; 10(7):e28618. PubMed ID: 38586389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer.
    Wang T; Liu Z; Guo S; Wu L; Li M; Yang J; Chen R; Xu H; Cai S; Chen H; Li W; Wang L; Hu Z; Zhuang Q; Xu S; Wang L; Liu J; Ye Z; Ji JY; Wang C; Chen K
    Oncotarget; 2014 Jun; 5(11):3611-21. PubMed ID: 25003983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAMK2N1 suppresses hepatoma growth through inhibiting E2F1-mediated cell-cycle signaling.
    Peng JM; Tseng RH; Shih TC; Hsieh SY
    Cancer Lett; 2021 Jan; 497():66-76. PubMed ID: 33068700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
    Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
    Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting CAMK2N1/CAMK2 inhibits invasion, migration and angiogenesis of non-small cell lung cancer by promoting autophagy and apoptosis via AKT/mTOR signaling pathway.
    Wang Q; Zhang C; Jiang H; He W
    Gene; 2024 Jun; 913():148375. PubMed ID: 38490509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional repression of SOCS3 mediated by IL-6/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasis.
    Huang L; Hu B; Ni J; Wu J; Jiang W; Chen C; Yang L; Zeng Y; Wan R; Hu G; Wang X
    J Exp Clin Cancer Res; 2016 Feb; 35():27. PubMed ID: 26847351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor suppressor gene inactivation during cadmium-induced malignant transformation of human prostate cells correlates with overexpression of de novo DNA methyltransferase.
    Benbrahim-Tallaa L; Waterland RA; Dill AL; Webber MM; Waalkes MP
    Environ Health Perspect; 2007 Oct; 115(10):1454-9. PubMed ID: 17938735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-182-5p Promotes Growth in Oral Squamous Cell Carcinoma by Inhibiting CAMK2N1.
    Li N; Nan CC; Zhong XY; Weng JQ; Fan HD; Sun HP; Tang S; Shi L; Huang SX
    Cell Physiol Biochem; 2018; 49(4):1329-1341. PubMed ID: 30205384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
    Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
    J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.